China's innovative pharmaceutical company, HENGRUI PHARMA (01276.HK) will raise $9.89 billion in its IPO at a cap offer price of $44.05, IFR quoted sources as saying.
It was previously rumored that, due to strong demand for IPO subscription, HENGRUI PHARMA would close institutional investor subscriptions a day early at 5 PM on Monday (19th). It is reported that institutional investor demand has topped the entire offering size.
(HK stocks quote is delayed for at least 15 mins.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。